All In Biotech

Drug Trial Radar · NCT07052929

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

A Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants With Invasive Ventilator-dependent X-linked Myotubular Myopathy

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

9

Planned (sponsor's estimate)

Start

Dec 15, 2025

Primary completion

Oct 31, 2027

Study completion Oct 31, 2027

Sponsor

Lead sponsor
Astellas Gene TherapiesAstellas (ALPMY)
Sponsor type
Industry
First posted
Jul 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, up to 36 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

X-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no approved therapies for XLMTM. The protein myotubularin is needed for muscle development, movement and breathing. A gene called MTM1 tells the body to make myotubularin. XLMTM is caused by changes, or mutations, in the MTM1 gene. Changes in the MTM1 gene cause low or no levels of myotubularin to be made, so the muscles do not work properly. Gene therapy is a way of getting a healthy copy of a gene into the body. This allows the body's cells to make a normal protein that may reduce disease symptoms. Researchers have developed ASP2957 to get a healthy MTM1 gene into the body. This could help improve muscle development and function in young children with XLMTM. In this study, ASP2957 will be given to humans for the first time. ASP2957 has the healthy MTM1 gene inside a type of empty (killed) virus. The virus delivers the healthy MTM1 gene directly into cells in the body. It's possible that some boys may have antibodies to the virus if they have previously been infected with a similar virus. The antibodies could stop ASP2957 from working properly and cause an immune reaction to ASP2957. To prevent this, the boys will also be given medicines to lower the immune system. The main aims of this study are to check the safety of ASP2957, how well it is tolerated, and to find a suitable dose of ASP2957. The study was designed in 2 phases. In Phase 1, different small groups of boys will receive lower to higher doses of ASP2957. Each boy will receive a single infusion of ASP2957. Any medical problems will be recorded for each dose. This is done to find a suitable dose of ASP2957 to use in Phase 2. In Phase 2, another small group of young boys will receive a single infusion of ASP2957. The most suitable dose of ASP2957 worked out from Phase 1 will be used. The boys will be checked for up to 1 year after their single infusion of ASP2957. After this, there will be the option for the boys to join another study so they will continue to be checked longer term.

Conditions

  • X-Linked Myotubular Myopathy

Interventions

  • ASP2957Genetic

    Intravenous infusion

  • MethylprednisoloneDrug

    Intravenous infusion

  • PrednisoloneDrug

    Route of administration based on locally sourced product

  • SirolimusDrug

    Route of administration based on locally sourced product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent adverse events (TEAEs)Time frame: Up to week 52
  2. Number of participants with adverse events of special interest (AESIs)Time frame: Up to week 52
  3. Number of participants with laboratory value abnormalities and/or adverse events (AEs)Time frame: Up to 52 weeks
  4. Number of participants with electrocardiogram (ECG) abnormalities and/or AEsTime frame: Up to 52 weeks
  5. Number of participants with echocardiogram (ECHO) abnormalities and/or AEsTime frame: Up to 52 weeks
  6. Number of participants with muscle magnetic resonance imaging (MRI) abnormalities and/or AEsTime frame: Up to 52 weeks
  7. Number of participants with histopathology abnormalities and/or AEs from muscle biopsyTime frame: Up to 52 weeks
  8. Number of participants with physical examinations abnormalities and/or AEsTime frame: Up to 52 weeks

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Lurie Children's Hospital

    Chicago, Illinois · Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • The University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • The Hospital for Sick Children

    Toronto, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.